Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 28;12(9):980.
doi: 10.3390/vaccines12090980.

Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates

Georgios Papazisis  1 , Xanthippi Topalidou  1
Affiliations
Review

Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates

Georgios Papazisis et al. Vaccines (Basel). .

Abstract

Respiratory Syncytial Virus (RSV) continues to pose a significant challenge, contributing to elevated hospitalization rates among children up to 5 years old, with a disproportionate burden on newborns and infants under 6 months old. The unique characteristics of the young immune system make it prone to altered responses to infections and vaccinations, requiring a tailored approach to disease prevention. The recent approval of the maternal RSV vaccine (brand name ABRYSVO) represents a pivotal advancement in preventive strategies among newborns and infants, marking a milestone in RSV research as the first market-approved maternal vaccine. The present review examines clinical trial data on both recent and previous vaccine candidates, as well as the licensed vaccine, focusing on the prevention of RSV disease in newborns and young infants through the passive acquisition of antibodies following maternal immunization. Additionally, it evaluates the safety profile of these vaccines.

Keywords: RSV vaccine; clinical trial; immunogenicity; infant immunity; maternal antibody transfer; maternal immunization; respiratory syncytial virus; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Newborn Infections. [(accessed on 5 July 2024)]. Available online: https://www.who.int/teams/maternal-newborn-child-adolescent-health-and-a....
    1. Hultquist J., Rios-Guzman E., Simons L., Dean T., Agnes F., Pawlowski A., Alisoltanidehkordi A., Nam H., Ison M., Ozer E., et al. Altered RSV Epidemiology and Genetic Diversity Following the COVID-19 Pandemic. Res. Sq. 2023 doi: 10.21203/rs.3.rs-3712859/v1. - DOI
    1. RSV Surveillance & Research. [(accessed on 5 July 2024)]; Available online: https://www.cdc.gov/rsv/php/surveillance/?CDC_AAref_Val=https://www.cdc.....
    1. Johannesen C.K., van Wijhe M., Tong S., Fernández L.V., Heikkinen T., van Boven M., Wang X., Bøås H., Li Y., Campbell H., et al. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. J. Infect. Dis. 2022;226:S29–S37. doi: 10.1093/infdis/jiac150. - DOI - PubMed
    1. Shi T., McAllister D.A., O’Brien K.L., Simoes E.A.F., Madhi S.A., Gessner B.D., Polack F.P., Balsells E., Acacio S., Aguayo C., et al. Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study. Lancet. 2017;390:946–958. doi: 10.1016/S0140-6736(17)30938-8. - DOI - PMC - PubMed

LinkOut - more resources